Filtered By:
Drug: Plavix
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 1913 results found since Jan 2013.
Clopidogrel Use in CYP2C19 Loss-of-Function Carriers With High Bleeding Risk After Percutaneous Coronary Intervention
CONCLUSIONS: Among patients with HBR, clopidogrel use in CYP2C19 LOF carriers was significantly associated with increased ischemic events after PCI.PMID:36792180 | DOI:10.1253/circj.CJ-22-0826
Source: Circulation Journal - February 15, 2023 Category: Cardiology Authors: Yuichi Sawayama Yukinori Tomita Soji Kohyama Yosuke Higo Kenji Kodama Kohei Asada Noriaki Yagi Megumi Fukuyama Atsushi Hayashi Wataru Shioyama Hiroshi Sakai Tomoya Ozawa Tetsuichiro Isono Daiki Hira Takashi Yamamoto Shin-Ya Morita Yoshihisa Nakagawa Source Type: research
CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials
ConclusionsCarriers of aCYP2C9 *2 or *3 LoF allele presenting with acute coronary syndrome and treated with clopidogrel did not have an increased risk for thrombotic events compared with noncarriers. Given the limited number of poor metabolizers, no firm conclusions could be drawn with regard to the thrombotic risk for patients carrying two CYP2C9 LoF alleles.
Source: American Journal of Cardiovascular Drugs - February 14, 2023 Category: Cardiology Source Type: research
Long-term risk, clinical management, and healthcare resource utilization of stable patients with coronary artery disease and post-myocardial infarction in Greece-TIGREECE study
CONCLUSIONS: Study results indicate that in the routine care of Greece one in ten patients experience a recurring CV event or death, mainly of ischemic origin, 1-3 years post-MI.PMID:36746373 | DOI:10.1016/j.hjc.2023.01.007
Source: Hellenic Journal of Cardiology - February 6, 2023 Category: Cardiology Authors: Filippos Anastasiadis Dimitrios Antoniadis Dimitrios Chountis Ioannis Mantas Ioannis Lekakis Moses Elisaf Charalampos Karvounis Athanasios Manolis Georgios Hahalis Ioannis Kogias Theodora Tourtoglou Dimitrios Gourlis Dimitrios Tsounis TIGREECE Study Inves Source Type: research
Rationale and design of a randomised double-blind 2 ×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES)
CONCLUSION: The INSPIRES trial will assess the efficacy and safety of intensive antiplatelet therapy and immediate intensive statin therapy begun within 72 hours of onset in decreasing the recurrent stroke at 90 days in patients with acute mild ischaemic stroke or high-risk TIA of intracranial or extracranial atherosclerosis origin.TRIAL REGISTRATION NUMBER: NCT03635749.PMID:36707080 | DOI:10.1136/svn-2022-002084
Source: Atherosclerosis - January 27, 2023 Category: Cardiology Authors: Ying Gao Yuesong Pan Shangrong Han Weiqi Chen Jing Jing Chunjuan Wang Yingying Yang Tingting Wang Xia Meng Xingquan Zhao Liping Liu Hao Li S Claiborne Johnston Pierre Amarenco Philip M Bath Yongjun Wang Yilong Wang INSPIRES Investigators Source Type: research
Pharmacogenomics in Stroke and Cardiovascular Disease Pharmacogenomics in Stroke and Cardiovascular Disease
This review provides an overview of the genetic variants that influence individual responses to aspirin, clopidogrel, warfarin, and statins and the clinical implications for stroke patients.Stroke
Source: Medscape Today Headlines - January 26, 2023 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes
CONCLUSIONS: Ticagrelor and prasugrel are increasingly used in patients with CCS undergoing PCI with similar 1-year efficacy and safety when compared to clopidogrel. Whether use of these agents can be beneficial in patients undergoing PCI for CCS with a high thrombotic and low bleeding risk warrants further study.PMID:36660810 | DOI:10.4244/EIJ-D-22-00654
Source: EuroIntervention - January 20, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Anoop N Koshy Gennaro Giustino Samantha Sartori Amit Hooda Yihan Feng Clayton Snyder Shabitri Dasgupta Kartik R Kumar Parasuram Krishnamoorthy-Melarcode Joseph Sweeny Sahil Khera Gregory W Serrao Raman Sharma George Dangas Annapoorna S Kini Roxana Mehran Source Type: research
Personalized antiplatelet therapy guided by clopidogrel pharmacogenomics in acute ischemic stroke and transient ischemic attack: A prospective, randomized controlled trial
Conclusion: The present study demonstrates that personalized antiplatelet therapy guided by clopidogrel pharmacogenomics and clinical characteristics can significantly improve the net clinical benefit of ischemic stroke or TIA patients during the 90-day treatment period without increasing bleeding risk.
Source: Frontiers in Pharmacology - January 18, 2023 Category: Drugs & Pharmacology Source Type: research
Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study
CONCLUSIONS: Patients suffering from cardiovascular events and mortality were characterized by prior cardiovascular events as compared to patients who did not experience any events. Antiplatelet therapy was not optimally protective despite high medication adherence, and HTPR was independently associated with the occurrence of events. More research is needed on alternative treatment strategies such as dual antiplatelet therapy or combinations with anticoagulant drugs.TRIAL REGISTRATION: The Medical Ethics Committee (METC) of the MUMC+ approved the study (NL63235.068.17) and the study was registered in the Netherlands Trial ...
Source: Atherosclerosis - January 10, 2023 Category: Cardiology Authors: B M M Kremers J H C Daemen H Ten Cate H M H Spronk B M E Mees A J Ten Cate-Hoek Source Type: research
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances
Kardiol Pol. 2022;80(12):1200-1210. doi: 10.33963/KP.a2022.0283.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease (CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with significant morbidity, mortality, and healthcare costs. Antiplatelet therapy has long been the mainstay of antithrombotic therapy for the prevention of first-ever and recurrent ASCVD events. More recently, however, randomized trials have demonstrated the benefits and cost-effectiveness of a dual pathway inhibition (DPI) strategy in acute and chronic ASCVD. When used in combinatio...
Source: Polish Heart Journal - January 5, 2023 Category: Cardiology Authors: Stephanie Carlin Tim Ac de Vries Andrzej Budaj John Eikelboom Source Type: research
